Spinraza (nusinersen) treatment helped school-age children with SMA be more independent in tasks involving their arms and ...

Ionis Pharmaceuticals IONS recently announced positive top-line results from the phase III ESSENCE study evaluating its ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $53.86, ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Biogen said U.S. and European regulators will review its applications seeking approval of a higher-dose regimen of its Spinraza drug for the neuromuscular disease spinal muscular atrophy.

Biogen BIIB announced positive initial data from the pivotal cohort (Part B) of its mid to late-stage study evaluating the safety and efficacy of a higher dose regimen of Spinraza (nusinersen ...

The firm expanded its neurology portfolio beyond MS, including the blockbuster rare neuromuscular disease drug Spinraza. We see Biogen as a firm in transition, as MS revenue fades and launches of ...

Biogen, in a press release. “Prior to receiving Spinraza at the start of RESPOND, we saw that participants had elevated neurofilament levels, as compared to healthy children suggesting ongoing ...

When it comes to spinal muscular atrophy, Biogen and Ionis Pharmaceuticals are two peas in a pod. After the success of Spinraza, the companies have picked another candidate to advance as a ...

April 19, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from the SPINRAZA ® (nusinersen) clinical development program aimed at optimizing outcomes for people ...